Compare Organon & Co. Common Stock (OGN) vs UiPath Inc (PATH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs UiPath Inc — how do they compare? Organon & Co. Common Stock trades at $13.76 (market cap $3.62B), while UiPath Inc trades at $12.91 (market cap $6.91B). The key difference: UiPath Inc is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while UiPath Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and UiPath Inc for 139 Days on average.
| OGN | PATH | |
|---|---|---|
Market Cap | $3.62B | $6.91B |
Volume | 2,892,999 | 26,239,123 |
Sector | Health | Technology |
52-Week High | $13.81 | $19.29 |
52-Week Low | $5.70 | $9.38 |
Typical Hold Time | 0 Days | 139 Days |
Enterprise Value | $11.04B | $5.70B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
UiPath (PATH) trades at $13.06, down 1.95% on the day, with a bullish technical signal from moving averages but neutral oscillators. Revenue growth is robust, increasing from $1.3B in 2024 to $1.43B in 2025, with a projected net profit of $362M in 2026. Recent news highlights expanded AI partnerships and raised guidance, though the stock faces near-term volatility.
The outlook is cautiously optimistic, with a consensus price target of $15.13 offering potential upside. Key opportunities include strong enterprise demand and AI monetization, while risks involve competitive pressures and execution challenges in achieving profitability targets. Analyst sentiment is mixed, with a majority hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →
